When the Prostate Spacer Fails: The SpaceOAR Problems Patients Are Not Always Told About

SpaceOAR is a hydrogel spacer placed between the prostate and the rectum before prostate cancer radiation therapy. The goal is simple: create more space between the prostate and the front wall of the rectum so that less radiation reaches the rectum during treatment. In many patients, this can reduce the risk of rectal irritation, rectal pain, bowel urgency, bleeding, and long-term bowel quality-of-life problems after prostate radiation.

The idea makes sense because the prostate sits very close to the rectum. When radiation is aimed at the prostate, the rectum can receive some unintended dose because of this close anatomy. A hydrogel spacer acts like a temporary cushion. It is injected into the space between the prostate and rectum and is gradually absorbed by the body over time.

Clinical studies have shown that hydrogel spacers can reduce rectal radiation exposure and improve bowel-related outcomes in appropriately selected patients. In a randomized clinical trial, spacer placement reduced the volume of rectum receiving high-dose radiation and was associated with fewer bowel quality-of-life declines compared with treatment without a spacer. ^[1]

However, the key phrase is “when it works as intended.” SpaceOAR is not just a product; it is also a procedure. Its benefit depends on accurate placement, correct injection technique, patient anatomy, radiation planning, and careful review of post-placement imaging. When SpaceOAR is misplaced, unevenly distributed, injected into the wrong tissue plane, or infiltrates the rectal wall, it may not give the expected protection. In rare cases, it may also contribute to complications.

A failed SpaceOAR does not always mean the device itself failed. More often, it means the hydrogel did not create the intended separation between the prostate and rectum, or it ended up in a location where it may not provide the expected benefit.

Patients may hear different terms, such as:

Failed SpaceOAR placement

Poor SpaceOAR placement

SpaceOAR misplacement

Uneven SpaceOAR distribution

Rectal wall infiltration

Hydrogel in the rectal wall

Spacer not creating enough space

Spacer too low, too high, or off-center

Inadequate prostate-rectum separation

In practical terms, failed SpaceOAR means one of three things. First, the spacer may not have created enough distance between the prostate and rectum. Second, the gel may have been placed unevenly, leaving part of the rectum still close to the prostate. Third, some of the hydrogel may have entered the rectal wall rather than staying in the intended space between the prostate and rectum.

These situations matter because the whole purpose of SpaceOAR is to lower rectal radiation exposure. If the spacer is not in the right plane or does not cover the correct area, the radiation plan may need closer review.

SpaceOAR is usually placed through the perineum, the area between the scrotum and anus, using image guidance. The physician guides a needle into the space between the prostate and rectum and injects material that forms a soft hydrogel. This gel pushes the rectum away from the prostate.

After placement, patients typically undergo radiation planning with magnetic resonance imaging, computed tomography, or both. These scans help the radiation oncology team see where the prostate, rectum, bladder, and spacer are located. The radiation plan is then designed to treat the prostate while keeping the rectal dose as low as possible.

When the spacer is well placed, it usually appears as a clear separation between the prostate and anterior rectal wall. Published reviews describe hydrogel spacers as a method to increase prostate-rectum distance and reduce rectal dose during prostate radiation therapy. ^[2]

But the procedure is technically sensitive. The space between the prostate and rectum is small. There may be scarring, adhesions, prior biopsy-related changes, previous surgery, prior radiation, inflammation, or anatomical variation. These factors can make ideal placement more difficult.

SpaceOAR misplacement means the hydrogel is not sitting where it should. The gel may be too close to the rectal wall, too close to the prostate, too far to one side, too low near the apex of the prostate, too high near the base, or irregularly spread.

A common concern is incomplete protection near the prostate apex. The apex is the lower part of the prostate, close to important urinary and rectal structures. If the spacer does not cover this region well, the rectum may still receive more radiation than expected in that area. A 2025 study specifically noted that hydrogel spacers can be unevenly distributed and that inadequate spacer positioning at the prostate apex is a situation encountered in clinical practice. ^[3]

Misplacement may not always cause symptoms right away. Many patients do not know there is a problem until the planning scan is reviewed. This is why imaging after SpaceOAR placement is important. A patient may feel fine, but the scan may show that the spacer is not giving the expected separation.

Rectal wall infiltration means that some of the hydrogel has entered or dissected into the wall of the rectum rather than staying completely in the intended space between the prostate and rectum.

This is different from the spacer simply being close to the rectum. In rectal wall infiltration, the gel may be within the rectal wall layers. This can be seen on magnetic resonance imaging or other planning imaging. The concern is that infiltrated gel may affect rectal tissue directly and may also change how the rectal wall receives radiation.

Rectal wall infiltration is important because it creates uncertainty. Some patients with rectal wall infiltration may do well and never develop serious rectal symptoms. In fact, a 2024 randomized trial analysis found that the depth of rectal wall infiltration was not associated with increased rectal toxicity up to 15 months after conventional prostate radiation therapy. ^[4]

However, this does not mean rectal wall infiltration should be ignored. Case reports and adverse event analyses have described severe rectal injury in some patients where hydrogel infiltration was suspected or considered a contributing factor. One published case described severe late rectal injury and a recto-urethral fistula after stereotactic body radiation therapy in the setting of significant hydrogel spacer rectal wall infiltration. ^[5]

So the most balanced way to understand rectal wall infiltration is this: it does not automatically mean a serious complication will happen, but it is not a finding that should be dismissed casually. It should be reviewed carefully by the treating radiation oncologist, and the radiation plan should account for the exact location of the spacer and the rectal wall.

No. A failed or imperfect SpaceOAR placement does not automatically mean prostate radiation therapy cannot proceed. Many patients can still receive radiation safely after careful planning.

The next step depends on what the imaging shows. If the spacer is slightly uneven but still provides useful separation, the radiation team may adjust the treatment plan. If there is little or no separation in a key area, the plan may need stricter rectal dose limits, a change in technique, or a discussion about whether the benefit of continuing as planned outweighs the risk.

If there is significant rectal wall infiltration, suspected rectal injury, infection, abscess, ulceration, or severe pain, radiation may be delayed until the situation is understood. In some cases, additional evaluation may be needed before treatment begins.

Postmarket reports and published analyses have described situations where SpaceOAR-related complications led to delays in starting radiation therapy, and in some cases patients did not proceed with radiation as originally planned. ^[6]

This is why patients should not think of SpaceOAR placement as a small step that is automatically successful. The planning scan is the proof. It tells the team whether the spacer is doing what it was meant to do.

Many patients have mild discomfort, pressure, soreness, or temporary urinary symptoms after SpaceOAR placement. Mild symptoms can occur because the procedure involves needle placement and hydrogel injection in a sensitive area.

However, certain symptoms should be reported promptly, especially if they are severe, worsening, or persistent.

Possible warning symptoms after SpaceOAR placement include:

Severe rectal pain

New or worsening pelvic pain

Painful bowel movements

Rectal bleeding

Fever or chills

Difficulty passing urine

Worsening urinary urgency or burning

Blood in the urine

Increasing rectal pressure

Constipation with severe pelvic discomfort

Pus, drainage, or signs of infection

New severe pain after radiation begins

Pain that gets worse instead of better

The manufacturer’s safety information lists potential risks such as pain, inflammation, infection including abscess, urinary retention, urgent need to urinate or pass stool, constipation, rectal spasm, rectal injury, ulcers, fistula, perforation, tissue necrosis, allergic reaction, embolism, fainting, and bleeding. ^[7]

This does not mean these complications are common. Most patients do not experience severe SpaceOAR complications. But knowing the red flags helps patients seek care early instead of assuming everything is normal.

A common problem for patients is knowing what is expected and what is not.

Mild soreness for a short time after the procedure may be expected. Temporary pelvic fullness can also happen. Some patients may notice urinary frequency or urgency for a short period. Mild spotting or discomfort may occur depending on the procedure and individual healing.

More serious symptoms include severe rectal pain, persistent bleeding, fever, worsening pain with bowel movements, inability to urinate, or symptoms that intensify after initially improving.

A retrospective study of 233 patients who received SpaceOAR reported that 24 patients experienced toxicity, with complications classified as mild or moderate, including pelvic pain, pelvic fullness, bleeding, and lower urinary tract symptoms. The same report noted that some hydrogel was injected into the rectal wall in a subset of patients, although this was not clinically significant in that study. ^[8]

The important takeaway is that SpaceOAR complications exist on a spectrum. Most are mild. Some are imaging findings without symptoms. A small number are serious. The goal is not to frighten patients, but to help them ask the right questions and recognize when follow-up is needed.

Failed SpaceOAR placement is usually detected through imaging, not symptoms alone. Magnetic resonance imaging is especially helpful because it shows soft tissues clearly. Computed tomography is also used during radiation planning and may be combined with magnetic resonance imaging for better definition.

Doctors look for several things on imaging:

How much space was created between the prostate and rectum

Whether the spacer is centered

Whether the spacer covers the prostate base, mid-gland, and apex

Whether the hydrogel is smooth or irregular

Whether any gel appears inside the rectal wall

Whether the rectal wall looks thickened or abnormal

Whether there is air, fluid, abscess, or other sign of injury

Whether the rectum still receives too much radiation dose in the proposed plan

A pictorial review of SpaceOAR imaging complications explains that hydrogel placement can create findings that affect image interpretation and that radiologists and radiation oncologists should be familiar with complications such as misplacement and rectal wall infiltration. ^[9]

For patients, this means a useful question is not simply, “Was SpaceOAR placed?” A better question is, “Did the post-placement magnetic resonance imaging or computed tomography show good separation, and was there any rectal wall infiltration?”

Even a well-placed spacer does not replace careful radiation planning. SpaceOAR is one tool used to reduce rectal dose, but the final safety depends on the radiation plan.

Radiation oncologists use dose constraints to limit how much radiation reaches organs at risk, including the rectum and bladder. If the spacer is well positioned, it may make it easier to meet these rectal dose goals. If the spacer is poorly positioned, the team may need to modify the plan.

This is especially important with high-dose radiation schedules, including stereotactic body radiation therapy, where larger doses are delivered per session. In that setting, precise anatomy and rectal dose control become very important. Severe rectal complications are rare, but when they occur, they can have major consequences.

Patients should ask whether the rectal dose constraints were met after SpaceOAR placement. They should also ask whether the plan was changed because of spacer position. These are practical questions, not confrontational ones.

In most cases, SpaceOAR is not simply “redone” immediately like replacing a bandage. The hydrogel forms after injection and remains for a period before gradually being absorbed. If placement is poor, the team usually evaluates the imaging and decides whether radiation can proceed safely with plan adjustments, whether treatment should be delayed, or whether another approach is needed.

There may be rare situations where additional procedures are considered, but this is highly individualized. The decision depends on the patient’s prostate cancer risk, urgency of treatment, anatomy, symptoms, imaging findings, rectal dose, and whether there is any sign of injury or infection.

Patients should not try to self-interpret the scan. A report that mentions “rectal wall infiltration” or “asymmetric spacer” does not automatically predict a bad outcome. But it should trigger a clear discussion with the treating team.

If the planning scan shows poor placement, misplacement, or rectal wall infiltration, patients may feel anxious. A structured conversation can help.

Useful questions include:

Did the spacer create enough separation between my prostate and rectum?

Is the hydrogel in the correct space, or is any part of it in the rectal wall?

Is the spacer evenly distributed from the base to the apex of the prostate?

Does the rectum still receive a safe radiation dose in my plan?

Were any changes made to the radiation plan because of the spacer position?

Is there any reason to delay radiation?

Do I need a rectal examination, additional imaging, or specialist review?

What symptoms should make me call urgently?

Would a different radiation schedule be safer in my situation?

Is stereotactic body radiation therapy still appropriate if the spacer placement is not ideal?

These questions help patients move the discussion from general reassurance to specific planning details.

Certain situations may raise more concern after SpaceOAR placement. These include severe pain immediately after the procedure, rectal bleeding, fever, signs of infection, imaging evidence of deep rectal wall infiltration, suspected rectal ulcer, abscess, perforation, or a radiation plan that cannot meet rectal dose constraints.

A history of prior pelvic radiation, rectal surgery, inflammatory bowel disease, severe rectal scarring, or difficult anatomy may also make the situation more complex. Patients with these factors should have a careful discussion before spacer placement and again after imaging.

Published reports show two realities at the same time: hydrogel spacers are often helpful and generally well tolerated, but rare serious complications have been reported. Reviews of adverse event databases have identified events that include rectal ulceration, fistula, abscess, perforation, and other significant injuries, although these events appear uncommon compared with the large number of procedures performed. ^[10]

No. This is one of the most important points for patients to understand.

Rectal wall infiltration is an imaging finding. It means hydrogel has entered the rectal wall. It does not automatically mean the rectum will be damaged. Some studies have found no clear link between rectal wall infiltration depth and increased rectal toxicity during follow-up after conventional prostate radiation therapy. ^[4]

At the same time, severe case reports exist. That means the finding should be handled thoughtfully. The risk may depend on how deep the infiltration is, how much gel is involved, whether the rectal wall appears injured, the radiation dose schedule, the exact rectal dose, and the patient’s underlying tissue health.

The safest interpretation is neither panic nor dismissal. Rectal wall infiltration should be reviewed, documented, and included in the radiation planning discussion.

If a patient suspects SpaceOAR did not work, the first step is to speak with the radiation oncology team and ask for a clear explanation of the planning imaging. Patients can request that the doctor review the scan findings with them in plain language.

It is reasonable to ask whether the spacer was well positioned, whether there was any rectal wall infiltration, and whether the treatment plan still meets rectal safety limits. If symptoms are present, especially rectal pain, bleeding, fever, or difficulty urinating, patients should report them promptly.

Patients should not stop or delay cancer treatment on their own. Prostate cancer treatment decisions should be made with the treating team. But patients also should not ignore symptoms or accept vague reassurance if imaging shows a meaningful abnormality. A second opinion from another radiation oncologist may be helpful if there is uncertainty about whether to proceed.

SpaceOAR is designed to protect the rectum during prostate cancer radiation therapy by creating space between the prostate and rectum. In many patients, it does this well and may reduce rectal radiation dose and bowel-related side effects.

But SpaceOAR does not work perfectly in every case. Misplacement, uneven distribution, inadequate separation, and rectal wall infiltration can occur. Sometimes these findings are mild and do not change treatment. Sometimes they require closer planning. Rarely, they may be associated with serious complications such as rectal ulceration, abscess, fistula, or perforation.

For patients, the most important point is this: the success of SpaceOAR should be confirmed on imaging before radiation begins. A spacer is only helpful if it is in the right place and the radiation plan uses that anatomy safely.

Patients should feel comfortable asking direct questions about spacer position, rectal wall infiltration, rectal dose, and warning symptoms. A well-informed patient is not being difficult. In prostate radiation therapy, small anatomical details can matter, and SpaceOAR placement is one of those details.

• SpaceOAR is meant to reduce rectal radiation exposure by creating distance between the prostate and rectum.
• Failed SpaceOAR may mean poor placement, uneven distribution, inadequate separation, or rectal wall infiltration.
• Rectal wall infiltration means hydrogel has entered the rectal wall rather than staying fully in the intended space.
• Rectal wall infiltration does not always cause symptoms or injury, but it should be reviewed carefully.
• Warning symptoms include severe rectal pain, rectal bleeding, fever, worsening pelvic pain, difficulty urinating, or painful bowel movements.
• Post-placement magnetic resonance imaging or computed tomography is important to confirm whether the spacer is working as intended.
• Radiation may still be possible after imperfect spacer placement, but the plan should be reviewed carefully to ensure rectal dose limits are safe.
• Patients should ask specific questions before starting radiation if the spacer position is abnormal.